Characteristics and Outcome of Patients with Early Complete Neurological Recovery after Thrombolysis for Acute Ischemic Stroke

C. Blinzler L. Breuer H.B. Huttner P.D. Schellinger S. Schwab M. Köhrmann

Department of Neurology, University of Erlangen-Nuremberg, Erlangen, Germany

Key Words

Complete recovery • Tissue plasminogen activator •
Acute ischemic stroke • Thrombolysis

Abstract

Background: Recombinant tissue plasminogen activator (rt-PA) is the only approved specific therapy for acute ischemic stroke. This study analyzes demographic and clinical characteristics of patients with early complete neurological recovery after thrombolysis. **Methods:** Data of 320 consecutive patients treated with rt-PA within 3 h of stroke onset at our facility between April 2006 and March 2009 were extracted from our prospective institutional stroke and thrombolysis database. Baseline demographic parameters, risk factors, clinical characteristics as well as neuroradiologic findings of patients with complete recovery 24 h after treatment and at hospital discharge were analyzed. Outcome was evaluated using the modified Rankin Scale at 90 days. **Results:** Thirty patients (9.4%) were asymptomatic 24 h after thrombolysis and 70 (22%) at hospital discharge. Patients with complete recovery were younger, more often male, had milder stroke symptoms, less often cardioembolic strokes, fewer bleeding complications and more often normal follow-up imaging. In addition, in-hospital time was shorter and these patients retained a better functional outcome at 90 days. Only 1 patient who had completely recovered at hospital discharge died during the follow-up time. In multivariate regression analy-

sis, only the National Institute of Health Stroke Score (NIHSS) on admission was predictive for complete recovery at both examined time points. **Conclusion:** Rapid complete recovery can be achieved in up to a fifth of acute stroke patients treated with thrombolysis. These patients are younger and have milder strokes, less often with cardioembolic origin. Better outcome and lower mortality are sustained at 3 months.

Copyright © 2010 S. Karger AG, Basel

Background

Recombinant tissue plasminogen activator (rt-PA) is currently the only approved therapy for acute ischemic stroke. After systemic thrombolysis, great variation in symptom recovery can be observed. In daily practice, some stroke patients greatly benefit from rt-PA and recover normal function shortly after application, suggesting successful recanalization. The majority of thrombolysis studies investigated long-term clinical outcome after 3 months or predictors of neurologic deterioration. There are very few data about determinants of early complete recovery after treatment with rt-PA. This study was performed to analyze demographic, clinical and radiological characteristics of patients with complete neurological recovery within 24 h after intravenous thrombolysis and at hospital discharge.

Methods

Patient Selection, Treatment and Evaluation of Outcome

The Erlangen Stroke and Thrombolysis Database is a prospective database of all patients with acute ischemic stroke treated at our institution (University Hospital Erlangen, Germany). It was established in April 2006 and contains baseline demographic and stroke-related data as well as treatment specifics, imaging information for each patient. Data of 1,661 stroke patients were included into the database between April 2006 and March 2009. Systemic thrombolysis was performed in 377 patients (thrombolysis rate 22.7%). To allow comparison with other studies, patients treated outside the 3-hour time window ($n = 54$) and with symptoms of nonischemic origin – according to the final diagnosis – were excluded from the analyses ($n = 3$). Thus 320 patients treated with intravenous thrombolysis within a 3-hour time window were included into the present study. A National Institute of Health Stroke score (NIHSS) is recorded 3 times daily by a stroke neurologist certified for NIHSS evaluation. Ninety-day outcome is evaluated by a neurologist as part of the general database independently of the present study. A modified Rankin Scale (mRS) score is derived using a semi-structured interview either in person or by telephone (patient, relatives) by a physician certified for mRS evaluation. The semi-structured interview was conducted on the basis of the mRS-SI [1], asking for the necessity of constant care, assistance for activities of daily living, ability to look after own affairs and restrictions in usual duties and activities.

In a first analysis, all patients with complete recovery at 24 h were compared with those with persisting symptoms. The same analysis was then carried out for patients asymptomatic at hospital discharge. Complete recovery was defined as no persisting symptoms from the present stroke. Symptomatic intracranial hemorrhage was defined using the ECASS-III criteria. All other intracranial hemorrhages were rated as asymptomatic.

Statistical Analysis

Statistical analysis was performed using PASW Statistics 17 (SPSS Inc., Chicago, Ill., USA). All data were tested for normality. Continuous data are expressed as mean and standard deviation or as median and interquartile range as appropriate; dichotomized variables are shown as numbers and percentages. Inter-group differences were assessed using the *t* test for normally distributed items, the Mann-Whitney *U* test for values with non-Gaussian distribution and the χ^2 test for dichotomous variables. Based on the results of univariate analysis, a logistic regression was performed including the factors that were associated with symptom recovery in the univariate model.

Results

Thirty patients (9.4%) were asymptomatic 24 h after treatment. These patients were younger ($p = 0.025$) and more often males ($p = 0.032$). Regarding risk factors, there was a lower rate of atrial fibrillation ($p = 0.030$) corresponding to fewer cardioembolic strokes. On admission, this patient group had a lower baseline NIHSS ($p <$

0.001) with a lower incidence of impaired consciousness ($p = 0.002$) and neglect ($p = 0.040$). Follow-up imaging was less likely to show ischemic changes ($p = 0.037$). The early recovery led to shorter in-hospital time ($p < 0.001$), and the functional outcome ($p < 0.001$) and mortality rates were more favorable. Complete patient characteristics as well as group comparisons are shown in table 1.

Seventy patients (22%) achieved full symptom recovery during their hospital stay. Again, asymptomatic patients had a lower rate of atrial fibrillation. The median baseline NIHSS was lower and temperature at presentation higher ($p = 0.007$) than in patients without complete recovery. However, the absolute difference in temperature between the groups was small (median 37.0 vs. 36.9°C). Patients had a lower rate of facial palsy ($p = 0.003$), paresis of the upper and lower extremities (both < 0.001), sensory loss ($p = 0.022$), neglect ($p < 0.001$) and impaired consciousness ($p < 0.001$). As in the patients with complete recovery within 24 h, patients that were asymptomatic at hospital discharge had a lower rate of imaging-proven infarction ($p = 0.037$). In-hospital time was shortened ($p < 0.001$) and, again, the functional outcome and mortality rates were more favorable. Complete patient characteristics as well as group comparisons are shown in table 2.

Overall, symptomatic intracranial hemorrhage occurred in 15 patients (4.7%). It was observed neither in the group with very early complete recovery (< 24 h) nor in the group with early complete recovery.

In multivariate regression analysis, only NIHSS on admission was predictive of complete recovery at both examined time points. In addition, normal follow-up imaging independently predicted complete recovery at hospital discharge. The results of the multivariate analysis are shown in table 3.

Discussion

Thrombolysis using rt-PA is the only approved reperfusion therapy for acute ischemic stroke. In daily practice, some stroke patients demonstrate dramatic early improvement of their symptoms and totally recover normal function shortly after drug administration. There are very few data published regarding patients without any disability shortly after symptom onset and during hospital stay.

Regarding baseline characteristics, younger age and lower admission NIHSS were found to be associated with complete early recovery. These factors were previously shown to predict improved outcome at 90 days in other studies. In a multivariate analysis of over 6,000 patients

Table 1. Demographics and baseline characteristics 24 h after symptom onset

	Asymptomatic (n = 30)	Symptomatic (n = 290)	p value
Demographics			
Age, years	69 (IQR 56–82)	73 (IQR 64–84)	0.025*
Female	7 (23%)	131 (45%)	0.032*
Clinical characteristics			
Days in hospital	6 (IQR 5–8)	9 (IQR 6–13)	<0.001*
Arterial hypertension	23 (77%)	237 (82%)	0.468
Atrial fibrillation	6 (20%)	118 (41%)	0.030*
Hypercholesterolemia	19 (63%)	161 (56%)	0.446
History of smoking	3 (10%)	35 (12%)	1.000
Diabetes mellitus	8 (27%)	108 (37%)	0.320
Patent foramen ovale	2 (7%)	11 (4%)	0.349
History of stroke	3 (10%)	45 (16%)	0.593
Coronary heart disease	8 (27%)	67 (23%)	0.655
Myocardial infarction	2 (7%)	36 (13%)	0.553
Peripheral arterial occlusive disease	5 (17%)	29 (10%)	0.344
Stroke characteristics			
NIHSS on admission	5 (IQR 3–7)	10 (IQR 5–15)	<0.001*
Left hemisphere	19 (63%)	159 (55%)	0.442
Right hemisphere	11 (37%)	105 (36%)	1.000
Brainstem/cerebellar	0	20 (7%)	0.236
Facial palsy	17 (57%)	210 (72%)	0.090
Paresis upper extremity	23 (77%)	245 (85%)	0.297
Paresis lower extremity	19 (63%)	211 (73%)	0.290
Sensory loss	11 (37%)	143 (50%)	0.122
Dysarthria	12 (40%)	142 (49%)	0.443
Aphasia	13 (43%)	140 (48%)	0.702
Neglect	1 (3%)	55 (19%)	0.040*
Impaired consciousness	0	59 (20%)	0.002*
Hemianopia	0	5 (2%)	1.000
Symptomatic intracranial hemorrhage	0	15 (5%)	0.377
Asymptomatic intracranial hemorrhage	2 (7%)	15 (5%)	0.666
Time window, min	120 (IQR 90–149)	115 (IQR 85–150)	0.828
mRS after 3 months	0 (IQR 0–1)	3 (IQR 1–4)	<0.001*
Follow-up mRS 0–1	24 (80%)	75 (26%)	<0.001*
Follow-up mRS 0–2	26 (87%)	112 (39%)	<0.001*
Death within 3 months	0	41 (15%)	0.021*
Ischemia in CT scan	18 (60%)	229 (79%)	0.037*
Vital signs			
Admission temperature, °C	37.1 (IQR 36.7–37.4)	36.9 (IQR 36.5–37.3)	0.176
Admission blood glucose, mg/dl	108.5 (IQR 92–135)	118 (IQR 98–146)	0.189
Cholesterol, mg/dl	190.77 (± 38.00)	193.01 (± 52.05)	0.819
Systolic blood pressure, mm Hg	155.67 (± 23.57)	158.81 (± 26.35)	0.409
Diastolic blood pressure, mm Hg	87.80 (± 12.12)	86.52 (± 17.99)	0.705

IQR = Interquartile range. * p < 0.05.

treated with rt-PA (SITS-MOST registry), Wahlgren et al. [2] showed that older age and a high NIHSS at baseline were significantly related to poor outcome. This was in concordance with the results of the multicenter stroke survey by Demchuk et al. [3], which demonstrated that mild-baseline stroke severity was the most important predic-

tor of a favorable outcome after thrombolysis. Additionally, clinical signs of severe stroke, such as impaired consciousness and neglect, were found more frequently in patients with persisting symptoms independently of examination time in this study. It is therefore not remarkable that patients with mild symptoms at baseline, indicating

Table 2. Demographics and baseline characteristics on hospital discharge

	Asymptomatic (n = 70)	Symptomatic (n = 250)	p value
Demographics			
Age, years	70.5 (IQR 59–78)	72.5 (IQR 62–81)	0.245
Female	26 (37%)	112 (45%)	0.277
Clinical characteristics			
Days in hospital	7 (IQR 5–8)	10 (IQR 7–13)	<0.001*
Arterial hypertension	59 (84%)	201 (80%)	0.603
Atrial fibrillation	17 (24%)	107 (43%)	0.005*
Hypercholesterolemia	45 (64%)	135 (54%)	0.136
History of smoking	9 (13%)	29 (12%)	0.835
Diabetes mellitus	25 (36%)	91 (36%)	1.000
Patent foramen ovale	2 (3%)	11 (4%)	0.741
History of stroke	9 (13%)	39 (16%)	0.706
Coronary heart disease	17 (25%)	58 (23%)	0.873
Myocardial infarction	9 (13%)	29 (12%)	0.835
Peripheral arterial occlusive disease	9 (13%)	25 (10%)	0.512
Stroke characteristics			
NIHSS on admission	5 (IQR 3–7)	11 (IQR 6–15)	<0.001*
Left hemisphere	19 (63%)	159 (55%)	0.442
Right hemisphere	11 (37%)	105 (36%)	1.000
Brainstem/cerebellar	0	20 (7%)	0.236
Facial palsy	38 (56%)	188 (75%)	0.003*
Paresis upper extremity	45 (64%)	223 (89%)	<0.001*
Paresis lower extremity	38 (54%)	192 (77%)	<0.001*
Sensory loss	25 (36%)	129 (52%)	0.021*
Dysarthria	30 (43%)	124 (50%)	0.344
Aphasia	33 (47%)	120 (48%)	0.893
Neglect	3 (4%)	53 (21%)	0.001*
Impaired consciousness	4 (6%)	55 (22%)	0.001*
Hemianopia	1 (1%)	5 (2%)	1.000
Symptomatic intracranial hemorrhage	0	15 (6%)	0.048*
Asymptomatic intracranial hemorrhage	3 (4%)	14 (6%)	1.000
Time window	120 (IQR 90–149)	110 (IQR 85–150)	0.559
mRS after 3 months	0 (IQR 0–1)	3 (IQR 2–4)	<0.001*
Follow-up mRS 0–1	52 (75%)	40 (18%)	<0.001*
Follow-up mRS 0–2	56 (81%)	74 (33%)	<0.001*
Death within 3 months	1 (1%)	40 (17%)	<0.001*
Ischemia in CT scan	37 (53%)	210 (84%)	<0.001*
Vital signs			
Admission temperature, °C	37.0 (IQR 36.8–37.4)	36.9 (IQR 36.4–37.2)	0.007*
Admission blood glucose, mg/dl	108.5 (IQR 91–137)	118 (IQR 100–146)	0.056
Cholesterol, mg/dl	194.38 (± 52.58)	192.32 (± 50.36)	0.768
Systolic blood pressure, mm Hg	159.74 (± 21.36)	159.33 (± 27.32)	0.906
Diastolic blood pressure, mm Hg	88.06 (± 15.39)	86.24 (± 18.09)	0.445

IQR = Interquartile range. * p < 0.05.

small-size cerebral ischemia, are more likely to gain full symptom recovery. As a result of neurological recovery, time in hospital was shorter in asymptomatic patients.

Male patients were more likely to fully recover after thrombolysis in our series. The influence of sex on the outcome after thrombolysis is a topic of controversy in

recent publications. In accordance with our findings, men were approximately 3 times more likely to have good functional outcomes in the GAIN study [4] and Delgado et al. [5] identified male sex as a factor for clinical improvement 48 h after intravenous thrombolysis. In contrast, no difference in outcome 90 days after stroke was

Table 3. Results of multivariate regression analysis

Time point	Variable	OR	p	95% CI
At 24 h	NIHSS on admission	0.794	<0.001	0.712–0.886
At discharge	NIHSS on admission	0.817	<0.001	0.758–0.880
	Ischemia in CT scan	0.365	0.002	0.192–0.693

–2 log likelihood at 24 h was 170.377 and 266.368 on discharge. Nagelkerkes R² was 0.183 at 24 h and 0.300 on discharge. OR = Odds ratio; 95% CI = 95% confidence interval.

found in the CASES [6] study in 1,110 thrombolized patients and the pooled analysis of the NINDS, ANLANTIS and ECASS (I and II) even showed that women benefited more from rt-PA compared with men [7]. Similar results were observed by Saposnik et al. [8], who demonstrated that female sex was associated with major neurologic improvement after rt-PA.

Atrial fibrillation is a recognized predictor for more severe strokes, a worse outcome and higher mortality in affected patients. In addition, atrial fibrillation was correlated with a reduced chance of recanalization 24 h after treatment with alteplase as demonstrated using transcranial Doppler ultrasound in a small study by Tandberg Askevold [9] as well as in a Japanese trial [10] showing atrial fibrillation to be associated with no recanalization in serial magnetic resonance angiography. In accordance with our data, Saňák et al. [11] described a worse outcome 90 days after intravenous thrombolysis in patients with atrial fibrillation just as Kimura et al. [12], who additionally found fewer patients with dramatic improvement after 7 days in their atrial fibrillation cohort.

Slightly higher baseline temperatures were observed in asymptomatic patients on hospital discharge in our study. Interestingly, the same observation was made in the Bergen stroke study [13], which found an inverse relationship between baseline body temperature and outcome and between rt-PA treatment and conservative therapy. A high baseline temperature was associated with a favorable outcome after 1 week in thrombolized patients just as low body temperature among patients not treated with rt-PA. This might be explained by the improved activity of the protease rt-PA on clot lysis at higher temperatures, exceeding the neuroprotective effect of low body temperature shortly after rt-PA administration. However, the small absolute difference in our study, and its effect on rt-PA activity and outcome may be statistically significant but not clinically relevant.

The fact that asymptomatic patients in our study were less likely to have ischemia on follow-up CT scans raises the question whether indeed we were treating transient ischemic attacks (TIAs) in the first place. This discussion, however, is theoretical since thrombolysis aims to ‘convert strokes into TIAs’ and is not an option to wait and see whether symptoms resolve without treatment. Furthermore, 24 h after thrombolysis, 60% of asymptomatic patients had a proven infarction on their follow-up CT scans and follow-up examinations using MRI may have shown an even higher percentage of cerebral ischemia. Currently there is no convincing diagnostic method available predicting spontaneous recovery under emergency room conditions and differentiating between stroke and TIA. Our data also failed to yield solid predictive clinical factors. Among baseline characteristics, only NIHSS on admission was predictive of complete recovery in multivariate analysis. Thus no other clinical variables can guide clinicians in the acute phase. The fact that no proven ischemia on follow-up imaging predicts complete recovery at hospital discharge is of course not known at baseline but may be useful in the early hospital course. In the future, more sophisticated baseline imaging models to predict tissue fate may to some extent help in deciding on treatment.

In addition to primary TIA, uncertainty remains whether full neurological recovery may due to a nonischemic process. According to current publications, a nonischemic origin of stroke symptoms with subsequent full recovery is not frequent. In a recent Swiss study, only 2.8% of 250 patients receiving intravenous thrombolysis could be identified as stroke mimics; another university stroke center reported that 3.5% of patients treated with rt-PA had a nonischemic diagnosis [14, 15]. In our series, only 3 treated patients had diagnoses other than stroke (0.8%).

After 3 months, a better outcome and lower mortality were recorded in patients without any disability after 24 h as well as on hospital discharge in this investigation. A similar finding was made in a subgroup analysis of the NINDS trial, assessing patients with neurological improvement ≥ 8 points or an NIHSS of 0 at 24 h [16]. This early improvement had a positive predictive value of 0.70 for a favorable 3-month outcome.

In conclusion, rapid complete recovery can be achieved in up to a fifth of acute-stroke patients treated with thrombolysis. These patients are younger and have milder strokes that are less often of cardioembolic origin. Better outcome and lower mortality are sustained at 3 months.

References

- 1 Wilson JT, Hareendran A, Grant M, Baird T, Schulz UG, Muir KW, Bone I: Improving the assessment of outcomes in stroke: use of a structured interview to assign grades on the modified Rankin Scale. *Stroke* 2002;33:2243–2246.
- 2 Wahlgren N, Ahmed N, Eriksson N, Aichner F, Bluhmki E, Dávalos A, Erilä T, Ford GA, Grond M, Hacke W, Hennerici MG, Kaste M, Köhrmann M, Larrue V, Lees KR, Machnig T, Roine RO, Toni D, Vanhooren G; Safe Implementation of Thrombolysis in Stroke-MONitoring STudy Investigators: Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-MONitoring STudy (SITS-MOST). *Stroke* 2008;39:3316–3322.
- 3 Demchuk AM, Tanne D, Hill MD, Kasner SE, Hanson S, Grond M, Levine SR; Multicentre tPA Stroke Survey Group: Predictors of good outcome after intravenous t-PA for acute ischemic stroke. *Neurology* 2001;57:474–480.
- 4 Elkind MS, Prabhakaran S, Pittman J, Koroshetz W, Jacoby M, Johnston KC; GAIN Americas Investigators: Sex as a predictor of outcome in patients treated with thrombolysis for acute stroke. *Neurology* 2007;68:842–848.
- 5 Delgado MG, Michel P, Naves M, Maeder P, Reichhart M, Wintermark M, Bogousslavsky J: Early profiles of clinical evolution after intravenous thrombolysis in an unselected stroke population. *J Neurol Neurosurg Psychiatry* 2010;81:282–285.
- 6 Kent DM, Buchan AM, Hill MD: The gender effect in stroke thrombolysis: of CASES, controls, and treatment-effect modification. *Neurology* 2008;71:1080–1083.
- 7 Kent DM, Price LL, Ringleb P, Hill MD, Selker HP: Sex-based difference in response to recombinant tissue plasminogen activator in acute ischemic stroke: a pooled analysis of randomized clinical trials. *Stroke* 2005;36:62–65.
- 8 Saposnik G, Di Legge S, Webster F, Hachinski V: Predictors of major neurologic improvement after thrombolysis in acute stroke. *Neurology* 2005;65:1169–1174.
- 9 Tandberg Askevold E, Naess H, Thomassen L: Predictors for recanalization after intravenous thrombolysis in acute ischemic stroke. *J Stroke Cerebrovasc Dis* 2007;16:21–24.
- 10 Kimura K, Iguchi Y, Yamashita S, Shibasaki K, Kobayashi K, Inoue T: Atrial fibrillation as an independent predictor for no early recanalization after IV-t-PA in acute ischemic stroke. *J Neurol Sci* 2008;267:57–61.
- 11 Saňák D, Herzig R, Král M, Bártková A, Zapletalová J, Hutýra M, Skoloudík D, Vlachová I, Veverka T, Horák D, Kaňovský P: Is atrial fibrillation associated with poor outcome after thrombolysis? *J Neurol* 2010;257:999–1003.
- 12 Kimura K, Iguchi Y, Shibasaki K, Iwanaga T, Yamashita S, Aoki J: IV t-PA therapy in acute stroke patients with atrial fibrillation. *J Neurol Sci* 2009;276:6–8.
- 13 Naess H, Idicula T, Lagallo N, Brogger J, Waje-Andreassen U, Thomassen L: Inverse relationship of baseline body temperature and outcome between ischemic stroke patients treated and not treated with thrombolysis: the Bergen stroke study. *Acta Neurol Scand* 2010;122:414–417.
- 14 Uchino K, Massaro L, Hammer MD: Transient ischemic attack after tissue plasminogen activator: aborted stroke or unnecessary stroke therapy? *Cerebrovasc Dis* 2010;29:57–61.
- 15 Winkler DT, Fluri F, Fuhr P, Wetzel SG, Lyrer PA, Ruegg S, Engelter ST: Thrombolysis in stroke mimics: frequency, clinical characteristics, and outcome. *Stroke* 2009;40:1522–1525.
- 16 Brown DL, Johnston KC, Wagner DP, Haley EC Jr: Predicting major neurological improvement with intravenous recombinant tissue plasminogen activator treatment of stroke. *Stroke* 2004;35:147–150.